Investigation of circulating antibodies to ANXA1 in breast cancer

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 1233-1236

  Huang, Yile ^a   Zhang, Cong ^b   Chen, Cairen ^a   Sun, Shilong ^b   Zheng, He ^a   Wan, Shuli ^a   Meng, Qingyong ^a   Chen, Yubin ^c   Wei, Jun ^d  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

ANXA1; Autoantibody; Breast cancer; Tumor immunity

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LIPOCORTIN 1; ANTI-IGG; ANTIBODY; ANTIIDIOTYPIC ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; BREAST TUMOR; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; TUMOR EMBOLISM;

AGED; ANNEXIN A1; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925503708     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2751-x     Document Type: Article

References (19)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–18.
2. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620. doi:10.1136/bmj.c3620.
3. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancer. J Natl Cancer Inst. 2000;92:1081–7.
4. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880–904.
5. Piura E, Piura B. Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol. 2010;2010:264926. doi:10.1155/2010/264926.
6. Piura E, Piura B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol. 2011;2011:982425. doi:10.1155.2011/982425.
7. Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126–34.
8. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012;33:1319–26.
9. Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, et al. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett. 2013;5:663–8.
10. Lacombe J, Mangé A, Solassol J. Use of autoantibodies to detect the onset of breast cancer. J Immunol Res. 2014;2014:574981. doi:10.1155/2014/574981.
11. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014;83:51–5.
12. Swa HL, Blackstock WP, Lim LH, Gunaratne J. Quantitative proteomics profiling of murine mammary gland cells unravels impact of annexin-1 on DNA damage response, cell adhesion, and migration. Mol Cell Proteomics. 2012;11:381–93.
13. Swa HL, Shaik AA, Lim LH, Gunaratne J. Mass spectrometry based quantitative proteomics and integrative network analysis accentuates modulating roles of annexin-1 in mammary tumorigenesis. Proteomics. 2014; [Epub ahead of print].
14. Wang W, Guan S, Sun S, Jin Y, Lee K-H, Chen Y, et al. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. Tumour Biol. 2014;35:4901–5.
15. Liu T, Song YN, Shi QY, Liu Y, Bai XN, Pang D. Study of circulating antibodies against CD25 and FOXP3 in breast cancer. Tumour Biol. 2014;35:3779–83.
16. Araujo TG, Marangoni K, Rocha RM, Maia YC, Araujo GR, Alcântar TM, et al. Dynamic dialog between cytokeratin 18 and annexin A1 in breast cancer: a transcriptional disequilibrium. Acta Histochem. 2014;116:1178–84.
17. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A. 2010;107:6340–5.
18. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.
19. Yom CK, Han W, Kim SW, Kim HS, Shin HC, Chang JN, et al. Clinical significance of annexin A1 expression in breast cancer. J Breast Cancer. 2011;14:262–8.